41342-91-0Relevant academic research and scientific papers
Use of 5-hydroxy-4H-benzo[1,4]oxazin-3-ones as β2-adrenoceptor agonists
Hoenke, Christoph,Bouyssou, Thierry,Tautermann, Christofer S.,Rudolf, Klaus,Schnapp, Andreas,Konetzki, Ingo
scheme or table, p. 6640 - 6644 (2010/06/12)
Novel β2-agonists with a 5-hydroxy-4H-benzo[1,4]oxazin-3-one moiety as head group are described. Systematic chemical variations at the phenethylamine residue of these compounds lead to the discovery of compound 6m as potent, full agonist of the β2-adrenoceptor with a high β1/β2-selectivity. Molecular modeling revealed an interaction between the carboxylic acid group of 6m and a lysine residue (K305) of the β2-receptor as putative explanation for the high observed selectivity. Further, compound 6m displayed in a guinea pig in vivo model a complete reversal of acetylcholine induced bronchoconstriction which lasted over the complete study time of 5 h.
Novel medicament combinations for the treatment of respiratory diseases
-
Page/Page column 33, (2008/06/13)
The present invention relates to new medicament combinations which contain in addition to one or more, preferably one, compound of general formula 1 wherein the groups R1, R2 and R3 may have the meanings given in the claim
Aerosol formulation for the inhalation of beta-agonists
-
Page/Page column 11, (2008/06/13)
The present invention relates to a propellant-free aerosol formulation which [contains] one or more compounds of general formula 1 wherein the groups R1, R2, R3 and X? may have the meanings given in the claims a
Novel medicaments for the treatment of respiratory diseases
-
Page/Page column 8, (2008/06/13)
The present invention relates to the use of the compounds of general formula 1 wherein the groups R1, R2 and R3 may have the meanings given in the claims and in the specification, for preparing a pharmaceutical composition
